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290 Comparison of totally implantable venous access device
complications in a cystic ﬁbrosis cohort and a haemodialysis
cohort
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Totally implantable venous access devices (TIVAD) are integral to the treatment of
cystic ﬁbrosis (CF) exacerbations. Complications are common and carry signiﬁcant
morbidity. We sought to determine the rate of complications in our centre and
to compare this to another cohort of patients with long term vascular access and
determine potential reasons for a disparity complication rate and type.
We performed a 5 year retrospective study of 51 patients currently attending an
Adult CF Centre who had at least one TIVAD and comparison data for 29 patients
attending a single haemodialysis (HD) unit over ﬁve years was used.
A total of 92 TIVADs were inserted in 51 CF patients and 75 tunnelled catheters
in HD patients. 16 CF patients (31%) experienced a complication compared to
18 HD patients (62%). 6 CF patients (11.7%) had evidence of line infections all
due to candidaemia while there were 16 line infections (55%) in the HD group,
none of whom had candidaemia. Candidaemia in the CF cohort was associated
with a higher frequency of exacerbations (p = 0.02) and a lower BMI (p = 0.49).
A complication rate of 0.27/1000 catheter days was noted in the CF group and a
rate of 0.65/1000 catheter days in the HD group.
Line infections were more common in HD patients, however rates (1.27 per dialysis
session) were below reported ﬁgures in the literature and the mean number of days
used per vascular device was higher. Candidaemia rates were signiﬁcantly higher
in CF, likely related to antibiotic use. Thrombosis rates were higher in HD group
(9.3% vs 6.5%) due to increase catheter bore; however it appears strict adherence
to heparinisation of TIVADs in CF patients would be of beneﬁt.
291 11 years of totally implantable vascular devices in a paediatric
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Objectives: Totally implantable vascular devices (TIVAD) are increasingly used in
children with cystic ﬁbrosis (CF) as they require regular courses of intravenous
antibiotics for chronic infections. We aimed to review our use of these devices
within our paediatric CF population.
Methods: We retrospectively reviewed all TIVADs inserted in our hospital to
paediatric CF patients over the past 11 years.
Results: A total of 34 TIVADs were inserted into 27 children with CF. Some
children received more than one TIVAD implantation during the review period.
The median age of insertion was 13 years (range: 4 months to 16 years). 79% of
TIVADs were inserted into patients colonised with Pseudomonas aeruginosa.
The main use of the TIVAD was for antibiotics; two children received TPN via
their TIVAD. Two TIVADs had their sites changed in theatre as the initial site
used was unsuccessful. Short-term post-operative complications were documented
in 6 TIVAD insertions but did not change management. The main long-term
complication was occlusion (17.6%). Infection of the TIVAD occurred in 11.8%.
Three of the four infected TIVADs grew Candida. All infected TIVADs were
removed. Dislodgement occurred in 8.8%. Those removed (14 cases) had a mean
duration of 3.3 years (range: 4 months to 7 years).
Conclusions: TIVADS appear to be reliable and safe. They provide excellent
vascular access over many years with low complication rates. TIVADs are inserted
by consultant paediatric surgeons within our unit. They are cared for and ﬂushed
regularly, mostly by the parents. TIVAD care and infection control techniques are
taught and regularly revised with the parents in order to minimise complications.
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Rationale: Peripherally-inserted central catheters (PICCs) have been proposed for
antibiotic therapies in children with cystic ﬁbrosis, but little data exists in adults.
Methods: Prospective follow-up of consecutive PICCs (Cook Medical) inserted in
adults with CF and non-CF bronchiectasis at Cochin University Hospital (Paris,
France).
Results: Between March 2009 and December 2011, 183 PICCs were prescribed
in 117 adults (67 CF and 50 non CF patients). Ultrasound guided placement of
catheter was successful in 95.6% (175/183) cases and no insertion complication
occurred. The mean±SD catheter dwell time was 15±9 days (range 1−96) and 120
catheters were used exclusively at home. Intravenous antibiotics were given using
continuous (n = 105) or intermittent (n = 70) infusions. PICC occlusion occurred
in 13.7% (24/175) and restoration of catheter patency required instillation of
urokinase in 10.3% (18/175) cases. Symptomatic upper limb deep vein thrombosis
occurred in 2.3% (4/175) cases and superﬁcial vein thrombosis also occurred in
2.3% (4/175) cases. Pain was mentioned by the patient in 18.2% (32/175) cases.
Premature removal of the catheter was necessary in 9.7% (17/175) cases due to
catheter displacements (n = 6), pain (n = 5), deep vein thrombosis (n = 1), suspicion
of sepsis (n = 6). After removal, all catheter tips were cultured in the microbiology
laboratory, but no pathogen was identiﬁed.
Conclusion: PICCs represent an alternative to totally implantable catheters in
patients who lose peripheral vein access. Although good infection control policy
appears to prevent catheter infection, pain, mechanical complications and deep vein
thrombosis were not infrequent.
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Objectives: As survival in CF continues to improve, the attitude of females towards
reproduction becomes increasingly important. We sought to identify the behaviour
and knowledge of our female CF patients towards contraception.
Methods: We asked 50 consecutive female CF patients (mean age 28 years [SD
1.9]) attending our large adult unit to complete a structured questionnaire evaluating
various aspects of contraception.
Results: Mean age of starting contraception use was 17 years (range 14−23), but
only 29% had discussed it prior to adult sector transition (2 adult diagnoses): of
these, most (85%) felt it was appropriately timed. Twenty-six (53%) have sought
advice in primary care (general practice) and 39% from family planning clinics.
Thirty-three patients (66%) are currently using contraception (mainly the combined
oral contraceptive pill). Twenty (40%) knew this may be less effective in CF,
antibiotic interaction being the most common reason. Twelve (24%) already have
children, and 50% were considering future pregnancy. Most patients (35, 70%)
would discuss these plans with the CF team prior to attempted conception.
Conclusion: Although contraception counselling is recommended prior to transi-
tion, there is still a lack of knowledge in adult CF patients. We need to ensure
that contraception information leaﬂets are readily available, and check patient
understanding at the annual screen. Ultimately, although patient choice dictates
the information source, specialist advice is required in relation to CF and should
be given by the CF team.
